Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, 2-part study of orally administered ALS-008176 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dosing and multiple ascending dosing in infants hospitalized with respiratory syncytial virus (RSV) infection

Trial Profile

A randomized, double-blind, placebo-controlled, 2-part study of orally administered ALS-008176 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dosing and multiple ascending dosing in infants hospitalized with respiratory syncytial virus (RSV) infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumicitabine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Alios BioPharma; Janssen Pharmaceutical KK; Janssen Research & Development
  • Most Recent Events

    • 14 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.
    • 28 Mar 2018 Status changed from recruiting to completed.
    • 09 Oct 2017 Planned End Date changed from 1 Nov 2017 to 30 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top